Schönherr E, Broszat M, Brandan E, Bruckner P, Kresse H
Institute of Physiological Chemistry and Pathobiochemistry, University of Münster, Waldeyerstrasse 15, Münster, D-48149, Germany.
Arch Biochem Biophys. 1998 Jul 15;355(2):241-8. doi: 10.1006/abbi.1998.0720.
It has been shown that small proteoglycans containing leucine-rich repeats in their core proteins can form complexes with TGF-beta. Decorin, a ubiquitously found molecule of the extracellular matrix, is the best-studied example. Therefore, binding domains on its core protein were investigated using recombinant decorin fragments generated as fusion proteins in prokaryotes. The peptide Leu155-Val260 immobilized by the polyhistidine tag on a nickel chelate column bound TGF-beta1 and -beta2 almost as effectively as the largest fragment (Asp45-Lys359) studied. Other peptides were less effective. For the two peptides Asp45-Lys359 and Leu155-Val260 dissociation constants in the nanomolar range for high-affinity binding sites were calculated in a solid-phase assay with immobilized TGF-beta2. Peptide Asp45-Lys359 also contained a lower affinity binding site. Domains with lower affinity were also found in peptides Asp45-Leu155 and Arg63-Gly190. Peptide Leu155-Val260 also formed complexes with TGF-beta in the liquid phase as determined by equilibrium gel filtration. Furthermore, F(ab') fragments of polyclonal antibodies against peptide Leu155-Val260 interfered with TGF-beta binding to peptide Asp45-Lys359 in a dose-dependent manner. Peptide Leu155-Val260, however, is only a weak competitor of the binding of wild-type decorin to reconstituted type I collagen fibrils. Therefore, independent binding sites of decorin for TGF-beta and type I collagen should exist. In support of this hypothesis saturable binding of TGF-beta1 and TGF-beta2 to collagen-bound native decorin could be demonstrated. The bound cytokine could be released in a biologically active form by collagenase treatment. Thus, decorin may play a biological role in storing this cytokine temporarily in the extracellular matrix and in thereby modulating an interaction of TGF-beta with its signaling receptors.
已表明,其核心蛋白中含有富含亮氨酸重复序列的小蛋白聚糖可与转化生长因子-β(TGF-β)形成复合物。核心蛋白聚糖是细胞外基质中普遍存在的一种分子,是研究得最为透彻的例子。因此,利用在原核生物中作为融合蛋白产生的重组核心蛋白聚糖片段,对其核心蛋白上的结合结构域进行了研究。通过多组氨酸标签固定在镍螯合柱上的肽Leu155-Val260与TGF-β1和-β2的结合几乎与所研究的最大片段(Asp45-Lys359)一样有效。其他肽的效果较差。对于肽Asp45-Lys359和Leu155-Val260,在固定化TGF-β2的固相分析中计算出高亲和力结合位点的解离常数在纳摩尔范围内。肽Asp45-Lys359还含有一个低亲和力结合位点。在肽Asp45-Leu155和Arg63-Gly190中也发现了亲和力较低的结构域。通过平衡凝胶过滤测定,肽Leu155-Val260在液相中也与TGF-β形成复合物。此外,针对肽Leu155-Val260的多克隆抗体的F(ab')片段以剂量依赖性方式干扰TGF-β与肽Asp45-Lys359的结合。然而,肽Leu155-Val260只是野生型核心蛋白聚糖与重组I型胶原纤维结合的弱竞争者。因此,核心蛋白聚糖与TGF-β和I型胶原应该存在独立的结合位点。为支持这一假设,可证明TGF-β1和TGF-β2与胶原结合的天然核心蛋白聚糖存在饱和结合。通过胶原酶处理,结合的细胞因子可以以生物活性形式释放。因此,核心蛋白聚糖可能在将这种细胞因子暂时储存在细胞外基质中以及调节TGF-β与其信号受体的相互作用方面发挥生物学作用。